{"nctId":"NCT01491802","briefTitle":"Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD","startDateStruct":{"date":"2012-01"},"conditions":["COPD"],"count":17,"armGroups":[{"label":"LAMA alone, then LAMA/LABA combination","type":"EXPERIMENTAL","interventionNames":["Drug: LAMA/LABA","Drug: LAMA"]},{"label":"LABA/LAMA combination, then LAMA alone","type":"EXPERIMENTAL","interventionNames":["Drug: LAMA/LABA","Drug: LAMA"]}],"interventions":[{"name":"LAMA/LABA","otherNames":["GSK573719+GW642444","umeclidinium (GSK573719) / vilanterol (GW642444)","Anoro ELLIPTA"]},{"name":"LAMA","otherNames":["umeclidinium"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stable moderate COPD\n* Post-bronchodilator FEV1/FVC\\<0.7 and 50%≤FEV1\\<80% predicted\n* Baseline Dyspnea Index ≤ 9 and MRC dyspnea scale \\>2\n* Cigarette smoking history at least 20 pack-years\n\nExclusion Criteria:\n\n* Presence of a significant disease other than COPD that could contribute to dyspnea and exercise limitation\n* Important contraindications to clinical exercise testing\n* Use of daytime oxygen\n* History of asthma","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Exertional Dyspnea Intensity at Isotime Exercise.","description":"Intensity of dyspnea (defined as breathing discomfort) at a standardized time (isotime) during constant work rate exercise tests as measured by the modified 10-point Borg scale. A rating of 0 represents no dyspnea up to a maximum of 10: a smaller rating is therefore an improvement. Isotime was defined as the highest exercise time in minutes completed in both post-treatment tests.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"2.4"},{"groupId":"OG001","value":"3.4","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Exercise Endurance Time","description":"Duration of constant work rate cycle exercise at 75% of maximum","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.82","spread":"6.15"},{"groupId":"OG001","value":"7.49","spread":"4.99"}]}]}]},{"type":"SECONDARY","title":"Inspiratory Capacity at Rest","description":"Measurements of pulmonary function included spirometry and body plethysmography. The resting inspiratory capacity (IC) values reported here are 90 minutes post-dose after 4 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"0.40"},{"groupId":"OG001","value":"2.36","spread":"0.86"}]}]}]},{"type":"SECONDARY","title":"Ventilation at Isotime Exercise","description":"Ventilation was measured during constant work rate exercise tests. Isotime was defined as the highest exercise time in minutes common to both post-treatment tests.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":"16.3"},{"groupId":"OG001","value":"47.5","spread":"18.4"}]}]}]},{"type":"SECONDARY","title":"Intensity of \"Unpleasantness of Breathing\" at Isotime Exercise","description":"Intensity rating (modified 10-point Borg scale) measured at a standardized time (isotime) during constant work rate exercise tests. A rating of 0 represents no \"unpleasantness of breathing\" up to a maximum of 10. An improvement would be noted as a decrease in the Borg scale rating. Isotime was defined as the highest exercise time in minutes common to both post-treatment tests.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"2.5"},{"groupId":"OG001","value":"3.3","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Inspiratory Capacity at Isotime Exercise","description":"Measurements of inspiratory capacity (IC) were conducted during constant work rate exercise tests. Isotime was defined as the highest time in minutes completed in both post-treatment tests.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":"0.56"},{"groupId":"OG001","value":"2.02","spread":"0.59"}]}]}]},{"type":"SECONDARY","title":"Diaphragm Electromyogram (EMGdi) at Isotime Exercise","description":"EMGdi was measured during constant work rate exercise tests via a multipair-electrode esophageal catheter. EMGdi expressed as a percentage of its maximum is used as an index of inspiratory neural drive. Isotime was defined as the highest exercise time in minutes common to both post-treatment tests.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":"17.4"},{"groupId":"OG001","value":"53.5","spread":"13.5"}]}]}]},{"type":"SECONDARY","title":"Tidal Esophageal Pressure (Pes) Swings at Isotime Exercise","description":"Tidal esophageal pressure (Pes) swings were measured via an esophageal balloon catheter during constant work rate exercise tests. Tidal Pes expressed relative to maximum is an index of respiratory effort. Isotime was defined as the highest exercise time in minutes common to both post-treatment tests.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":"17"},{"groupId":"OG001","value":"28","spread":"20"}]}]}]},{"type":"SECONDARY","title":"Mean Expiratory Flow at Isotime Exercise","description":"Mean expiratory flow was measured during constant work rate exercise tests. Isotime was defined as the highest exercise time in minutes common to both post-treatment tests.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":"0.80"},{"groupId":"OG001","value":"2.34","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1)","description":"Measurements of pulmonary function included spirometry and body plethysmography. Values reported are 90 minutes post-dose after 4 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":"0.40"},{"groupId":"OG001","value":"1.72","spread":"0.46"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":17},"commonTop":["COPD exacerbation","Pancreatitis"]}}}